Section 4.2: Differentials in Respiratory Conditions

Differentials in Respiratory Conditions

Evaluating respiratory complaints in primary care requires understanding airway pathophysiology, patient risk profiles, spirometric diagnostics, and clinical assessment techniques. The FNP must distinguish among asthma, chronic obstructive pulmonary disease (COPD), community-acquired pneumonia (CAP), and acute bronchitis to ensure appropriate, guideline-based management.

1. Asthma vs. COPD: Pathophysiology and Diagnostics

Asthma and COPD are both obstructive lung diseases characterized by airflow limitation, but they differ significantly in pathophysiology, clinical presentation, and diagnostic criteria.

Pathophysiological Differences

• Asthma: Chronic airway inflammation driven by mast cells, eosinophils, IgE, and CD4+ T lymphocytes. This leads to airway hyperresponsiveness and reversible bronchoconstriction, frequently triggered by allergens or viral infections.
• COPD: Progressive, persistent inflammatory response driven by neutrophils, macrophages, and CD8+ T lymphocytes. It is characterized by small airway narrowing (chronic bronchitis) and alveolar destruction (emphysema), typically resulting from long-term exposure to noxious particles (most commonly tobacco smoke).

Clinical and Risk Profiles

• Asthma: Often begins in childhood or young adulthood. Risk factors include a personal or family history of atopy (asthma, allergic rhinitis, eczema). Symptoms are episodic, variable, and often worse at night or in response to triggers (cold air, exercise, allergens).
• COPD: Typically presents in individuals over age 40 with a significant smoking history (>10 pack-years) or occupational exposure. Alpha-1 antitrypsin (AAT) deficiency should be suspected in patients presenting with emphysema at a young age (<45 years) or with no smoking history. Symptoms are progressive, persistent, and include dyspnea on exertion and chronic sputum production.

Spirometry: The Diagnostic Gold Standard

To establish a diagnosis, spirometry is performed before and 10–15 minutes after administering a short-acting beta-agonist (SABA; e.g., albuterol 200–400 mcg):

• FEV1/FVC Ratio: A post-bronchodilator FEV1/FVC ratio <0.70 is the diagnostic threshold for COPD, representing fixed, non-reversible airflow limitation. In asthma, the ratio may be normal between exacerbations, or it may improve to normal post-bronchodilator.
• Bronchodilator Reversibility: GINA guidelines define a positive bronchodilator response as an increase in FEV1 of >12% and >200 mL from baseline. COPD is characterized by a lack of significant reversibility, although minor improvements may occur.

2. Asthma Severity Classification (GINA Guidelines)

For patients not currently receiving long-term controller therapy, asthma severity is classified based on clinical symptoms and lung function prior to initiating treatment:

• Intermittent: Symptoms <=2 days/week, nighttime awakenings <=2 times/month, SABA use <=2 days/week, no interference with normal activity, FEV1 >80% predicted.
• Mild Persistent: Symptoms >2 days/week but not daily, nighttime awakenings 3–4 times/month, SABA use >2 days/week but not daily, minor limitation in activity, FEV1 >=80% predicted.
• Moderate Persistent: Daily symptoms, nighttime awakenings >1 time/week (but not nightly), daily SABA use, some limitation in activity, FEV1 60–80% predicted.
• Severe Persistent: Symptoms throughout the day, nighttime awakenings nightly, SABA use multiple times daily, extreme limitation in activity, FEV1 <60% predicted.

3. COPD Staging and Grouping (GOLD Guidelines)

COPD classification incorporates spirometric staging and the GOLD ABE clinical assessment tool:

Spirometric Staging (Based on post-bronchodilator FEV1 in patients with FEV1/FVC <0.70)

• GOLD 1 (Mild): FEV1 >=80% predicted.
• GOLD 2 (Moderate): 50% <= FEV1 < 80% predicted.
• GOLD 3 (Severe): 30% <= FEV1 < 50% predicted.
• GOLD 4 (Very Severe): FEV1 < 30% predicted.

GOLD ABE Assessment Tool

Patients are placed into one of three groups based on symptom severity (evaluated by the modified Medical Research Council [mMRC] dyspnea scale or COPD Assessment Test [CAT]) and exacerbation history:

• Group A: Low symptoms (mMRC 0–1 or CAT < 10) and low exacerbation history (0 or 1 moderate exacerbation not leading to hospital admission).
• Group B: High symptoms (mMRC >=2 or CAT >= 10) and low exacerbation history.
• Group E (Exacerbation-prone): High risk of exacerbations, defined as >=2 moderate exacerbations OR >=1 exacerbation leading to hospital admission, regardless of symptom scores. This unified group emphasizes that exacerbation risk drives therapy choice.

4. Pneumonia vs. Acute Bronchitis

Distinguishing lower respiratory tract infections from bronchitis is essential to prevent diagnostic errors and inappropriate prescribing.

Community-Acquired Pneumonia (CAP)

CAP involves infection of the lung parenchyma. Clinical features include fever, productive cough with purulent sputum, pleuritic chest pain, dyspnea, and tachypnea. Physical examination reveals signs of pulmonary consolidation:

• Increased Tactile Fremitus: Palpating the chest wall while the patient speaks ("ninety-nine") reveals increased vibrations over the consolidated lobe.
• Dullness to Percussion: Heard over fluid-filled consolidated tissue.
• Auscultation Findings: Bronchial breath sounds, crackles, and positive vocal resonance tests, including egophony (auscultated "E" sounds like "A"), bronchophony (spoken words are heard loudly), and whispered pectoriloquy.
• Diagnosis Confirmation: Chest X-ray (CXR) is the diagnostic standard, demonstrating lobar consolidation or interstitial infiltrates.

Acute Bronchitis

Acute bronchitis is a self-limiting inflammation of the large airways. Clinical signs include a cough (productive or non-productive) lasting 1–3 weeks, often following an upper respiratory infection. Key differences from pneumonia include:

• Absence of Systemic Signs: Patients lack high fever, severe tachypnea, or tachycardia.
• Normal Lung Exam: No physical signs of consolidation. Wheezing or rhonchi may be auscultated, but they often clear or change pitch after coughing.
• CXR Findings: A chest X-ray is normal or shows non-specific bronchial wall thickening; it is not indicated unless pneumonia is suspected.
• Etiology: Over 90% of cases are viral. Antibiotic therapy is not recommended for uncomplicated acute bronchitis, making supportive care the standard of care.